Articles from ICPO Foundation

ICPO accreditation following international theranostics guidelines and ICPO Academy for Theranostics will fuel the partnership right from start.

Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb company.

Over 220 experts from around the globe came together to shape the future of radiotheranostics for better cancer patient outcomes

Launching the "ICPO Academy for Theranostics" and creating its global network of ICPO Centers, the foundation has become an international leader in sharing knowledge and shaping standards in its field.

The world-class scientific program was provided by 35 international experts 

The Munich pilot center will serve as a functional demonstrator for ICPO. The Foundation will provide accreditation guidelines and certified training for improved patient outcomes.

This pioneering global trial finder tool powered by AI will be presented at the EANM Congress 2024 in Hamburg from Oct 20-22, 2024

This cooperation strengthens global educational standards for radiotheranostics and will scale patient access to a new generation of effective cancer therapeutics in United Arabic Emirates.

This collaboration enhances global educational benchmarks in radiotheranostics and aims to expand patient access to a new era of effective cancer therapeutics in South Africa.

Save the date in your event calendar:

Prof. Dr. Tadashi Watabe, Medical Doctor at Osaka University Hospital and Associate Professor at Osaka University, is an active member of the ICPO Foundation

Today marks a significant milestone for the ICPO ACADEMY FOR THERANOSTICS, a groundbreaking initiative developed by the International Centers for Precision Oncology (ICPO) Foundation. We are thrilled to announce the prestigious accreditation form the Union Européenne des Médecins Spécialistes (UEMS), an esteemed institution dedicated to enhancing medical education and professional standards across Europe. This accreditation not only underscores our unwavering commitment to excellence but also solidifies our position as a leader in advancing medical education worldwide. As the foremost European organization representing national associations of medical specialists, the UEMS plays a crucial role in advancing the delivery of high-quality healthcare, promoting continuous professional development, and safeguarding patient safety. Furthermore, the mutual recognition agreement extends beyond Europe, with the American Medical Association (AMA) acknowledging UEMS-EACCME credits, thus expanding the global reach and influence of our educational programs. The primary audience of the ICPO Academy for Theranostics includes clinicians, researchers, physicists, and radiochemists, as well as nurses and technologists, who seek to integrate Radiomolecular Precision Oncology into patient care.

The International Centers for Precision Oncology (ICPO) Foundation and the Brazilian Society of Nuclear Medicine (SBMN) today announced a collaboration to advance the field of Radiomolecular Precision Oncology (RPO) in Brazil. This collaboration is aimed at deploying the ICPO Academy for Theranostics and later establishing ICPO Centers in Brazil and contribute to the global advancements in the field.

Today, the ICPO Academy for Theranostics, a transformative initiative developed by the International Centers for Precision Oncology (ICPO) Foundation, announced a sponsorship agreement with ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, to fund 100 stipends for the Academy's online education program. The primary audience of the ICPO Academy for Theranostics are clinicians, researchers, physicists, and radiochemists as well as nurses and technologists, who seek to integrate Radiomolecular Precision Oncology in patient care. The stipends will be offered in China, India, Africa and Latin America.

Today, the Academy for Theranostics, a transformative initiative developed by the International Centers for Precision Oncology (ICPO) Foundation, announced that ADACAP (Advanced Accelerator Applications International S.A), a Novartis company, has signed a grant agreement to fund 130 stipends for the Academy's online education program. The primary beneficiaries of the ICPO Academy for Theranostics include clinicians, researchers, physicists, radiochemists, as well as nurses and technologists, all dedicated to integrating Radiomolecular Precision Oncology (RPO) into patient treatment. RPO brings a spectacular improvement in cancer care while today’s global demand largely exceeds patient access. Standardized education is key to bridge this gap. Radiotheranostics has the power to offer novel patient-focused precision oncology treatments according to the principle: “We treat what we see and see what we treat”. The ICPO Foundation, through its global Community, will identify promising recipients for the Novartis stipends, enabling young professionals to access world-class education and laying the ground for their future in theranostics.

Today, the International Centers for Precision Oncology (ICPO) Foundation and MISR Radiology Center (MRC) announced their cooperation in establishing MRC as one of the global ICPO Collaborating Centers. The parties intend to enable a growing number of patients worldwide access to a new generation of effective cancer therapeutics and promote research and development in the fields of Radiomolecular Precision Oncology (RPO). MRC will support the joint development and enhancement of best practice standards and their implementation in the internationally active ICPO Academy (Academy for Precision Oncology) in Egypt and North Africa.

This October 12th and 13th, 2023, the International Centers for Precision Oncology (ICPO) Foundation has successfully hosted its 3rd ICPO Forum for Theranostics in Precision Oncology physical on the Science Campus in Garching Munich. The Forum is a bi-annual tradition for the German foundation which is working to enable growing numbers of Cancer Patients worldwide to get access to highly effective diagnostics and treatments in Radiomolecular Precision Oncology.

The International Centers for Precision Oncology (ICPO) is a German foundation working to enable growing numbers of Cancer Patients worldwide to get access to highly effective diagnostics and treatments in Radiomolecular Precision Oncology.

The International Centers for Precision Oncology (ICPO) Foundation and NTP Radioisotopes SOC Ltd. (NTP) today announced a collaboration to promote international education standards in Radiomolecular Precision Oncology (RPO) and support the establishment and expansion of a global network of Theranostics Centers. The overarching goal of the collaboration is to substantially increase patient access to advanced RPO imaging and therapies with a special focus on the African continent.

Since 2019 the International Centers for Precision Oncology (ICPO) is a German foundation working to enable growing numbers of Cancer Patients worldwide to get access to highly effective diagnostics and treatments in Radiomolecular Precision Oncology. ICPO believes that scaling patient access can best be achieved through building a global community and international network of Precision Oncology Centers based on shared passion, knowledge, standards, training, and blueprints, essentially building a common operating model for dedicated and optimized Precision Oncology Centers.

The International Centers for Precision Oncology (ICPO) Foundation and Fortis Memorial Research Institute (FMRI) today announced a reference center collaboration to promote international education standards in Radiomolecular Precision Oncology (RPO) and support the establishment of new Theranostics Centers in India. The partnership aims to enhance patient access to advanced RPO imaging and therapies in India and contribute to the global advancements in the field.

The International Centers for Precision Oncology (ICPO) Foundation and the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) today announced a collaboration to promote international education standards in Radiomolecular Precision Oncology (RPO) and support the establishment and expansion of a global network of Theranostics Centers. The overarching goals of these efforts are to increase patient access to advanced RPO imaging and therapies worldwide, with a special focus on the more than 50 countries represented by WARMTH members.

The International Centers for Precision Oncology (ICPO) Foundation and Melbourne-based PreMIT Pty Ltd (PreMIT), today announced a collaboration to develop a global network of Precision Oncology and Theranostics centers. Through their joint efforts, the parties intend to scale access to Radiomolecular Precision Oncology for cancer patients globally and to foster research & industry partnerships.

The International Centers for Precision Oncology (ICPO) Foundation is pleased to announce the appointment of Taranjit Singh, B J Madan & Co.’s CEO, to the ICPO Board of Curators and welcoming B J Madan & Co., New Delhi, India, to the growing group of active supporters.